Subscribe
Be the first with the news that moves the market- Pharmaceutical developer Arch Biopartners has received recognition for one of its trialled drugs in a published University study
- The company’s drug, tentatively named ‘AB569’, was covered in a trial by the University of Cincinnati College of Medicine
- AB569 is engineered to combat pathogens that resist medical treatment — particularly in the lungs
- The findings by the University found its response to be successful
- Shares in ARCH on the Toronto Stock Exchange closed on Friday with a 3.66 per cent premium — a price of 0.85 cents per share.
Toronto based and Stock Exchange listed Arch Biopartners has received recognition for one of its tentative drugs in a published university study.
The drug, currently named ‘AB569’, is said to promote antibacterial treatments — especially in the lungs.
AB569 garnered its recognition in a study by the University of Cincinnati College of Medicine. A team assisted by senior author Dr Daniel Hassett, a Professor of the University, found AB569 to be generally successful in combating drug-resistant bacteria.
“AB569 kills these pathogenic bacteria by targeting their DNA, RNA and protein biosynthesis as well as energy and iron metabolism in bacteria at concentrations that do not harm human cells,” Dr Daniel said.
“Our data implicate that AB569 is a safe and effective means that could be applied to eradicate these superbugs.”
Findings from the research were published in the journal: ‘Proceedings of the National Academy of Sciences of the United States (PNAS)’, in the article ‘AB569, a nontoxic chemical tandem that kills major human pathogenic bacteria’.
The AB569 drug was tested against six particular pathogens, known collectively as ‘ESKAPE’, that typically cause hospital-required treatment (usually causing pneumonia).
“These superbugs have an ingenious mechanism of being able to resist traditional antibiotic therapies by a vast number of acquired strategies,” Dr Daniel said.
“Antibiotics affect specific processes in the bacteria, but not all of them. AB569 affects multiple processes at once leaving the exposed bacteria simply overwhelmed.”
Arch Biopartners currently has an exclusive commercial licence with the University of Cincinnati. AB569 is so far under ‘orphan drug status’ with the American Food and Drug Administration.
Shares in ARCH on the Toronto Stock Exchange closed on Friday with a 3.66 per cent premium — a price of 0.85 cents per share.
